ALX Oncology Holdings Inc. (ALXO)
NASDAQ: ALXO · Real-Time Price · USD
0.6470
-0.0136 (-2.06%)
Aug 14, 2025, 11:22 AM - Market open
ALX Oncology Holdings Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
80
Market Cap
34.58M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ALXO News
- 1 day ago - ALX Oncology Holdings Inc. (ALXO) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 9 days ago - ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025 - GlobeNewsWire
- 2 months ago - ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference - GlobeNewsWire
- 3 months ago - ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event - GlobeNewsWire
- 3 months ago - ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025 - GlobeNewsWire
- 3 months ago - ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025 - GlobeNewsWire